Thank you, Mr. Chairman.
I do have some opening remarks.
Before answering questions, I will review the measures taken by my department when it became aware of the prolonged shutdown of the NRU reactors in Chalk River and the ensuing shortage of medical isotopes.
Of course, I'm addressing this issue, Mr. Chair, from my perspective as the federal Minister of Health and my mandate to help protect, maintain, and improve the health of Canadians.
As members know, the Chalk River reactor is a critical source of medical isotopes in Canada and indeed worldwide. Radioisotopes are used in diagnosing and treating cancer and cardiovascular disease. They are relied upon by health care facilities in Canada and around the world.
In Canada alone, approximately 30,000 patients per week undergo nuclear medicine scans. As well, Chalk River provides isotopes for 76,000 tests per day worldwide. When the NRU reactor was shut down from November 18 to mid-December, I can tell you it significantly reduced the supply of these isotopes in Canada and around the world. In all, MDS Nordion estimates a 65% reduction of the isotopes in Canada during this period.
As soon as this fact was announced on December 5, we started taking immediate action. We began working with provinces and territories and with health system partners to determine the extent of the shortage and to assess options to respond effectively.
We communicated with nuclear medicine specialists to assess how best to manage the impacts on the health care system and on patients. We contacted 773 health care facilities across Canada, including up to 245 nuclear medicine facilities to determine the severity of the shortage. I personally communicated with provincial and territorial health ministers, and my officials kept in close contact with their provincial and territorial counterparts closely monitoring the situation as it evolved.
We also contacted other international agencies to determine the extent of the shortages worldwide. We quickly formed a group of experts from the fields of oncology, cardiology, and nuclear medicine, as well as representatives of the Canadian Medical Association and the Canadian Society of Nuclear Medicine.
I want to refer, if I may, to the information we received from this group. Some people out there seem to think there really wasn't a health crisis after all and our response was overblown. Let me say that based on the information we gained from our advisory group, such people are absolutely wrong. This advisory group made it crystal clear to our government that we certainly were in the midst of what was a growing health crisis and one that needed action. This group estimated that approximately 10% of affected patients were facing life and death decisions and another 30% to 40% were facing the risk of underequipped physicians making inappropriate diagnostic and treatment decisions. In short, Mr. Chair, the situation was not sustainable and certainly not acceptable.
In realizing the impacts of the shortage, the Canadian Medical Association issued a statement saying that nuclear medicine services were now being rationed across Canada; that patients were deprived of timely access to critical diagnostic procedures; that this was impacting diagnostic services, timely surgery, and therapy planning, placing patients increasingly at risk; and that the decision to take the reactor off-line for an extended period of time had already affected critical medical management decisions and the numbers affected would escalate every day that the shutdown was in effect.
The most severe shortages were felt in smaller rural and remote centres, particularly in Atlantic Canada. One hospital in Newfoundland told me that most of their staff in nuclear medicine had been sent home because without isotopes no work could be done. Their last generator expired at noon on December 7 and they had no backup. All appointments for patients had been cancelled and all emergency patients were being turned away. For the health of Canadians we needed production to resume to prevent even more hospitals from going without. In the short term, the situation was threatening lives. If left unchecked over the long term, the situation would have started taking lives.
Given the serious consequences to the health of Canadians, we had a responsibility to seek information from the Canadian Nuclear Safety Commission about ways to resolve the growing health crisis. We wanted to see if there could be an expeditious hearing to consider the merits of AECL's safety case without in any way directing that the commission reach a particular conclusion, but as we know, such a hearing did not take place.
Our government then issued a directive stipulating that the commission's decisions take into account the health of Canadians who are dependent upon nuclear substances for medical purposes, but that had no effect. As a result, the government had to take the decisive action on December 12, proposing C-38 to Parliament. Following all-party passage of that bill, the reactor came back online on December 19 and isotope deliveries resumed during the holidays.
I believe we acted in such a way that we balanced the likelihood of a potential incident of nuclear safety with the real certainty--the real certainty--of a serious and growing health crisis. For this action, the Canadian Medical Association and the Canadian Society of Nuclear Medicine publicly thanked the Prime Minister, myself, and all members of Parliament “of all political stripes”, to use their words, for the fast legislative action.
Some have said we could have obtained extra supply from international sources. Indeed, we moved quickly to try to obtain supply from the four other suppliers in France, Belgium, the Netherlands, and South Africa. We contacted European suppliers. They were willing to help, but they found they could only increase their output by 10% to 15%, which would not be enough to meet Canadian demand. Also during this time, French and South African reactors were going through their own routine maintenance and were unable to meet Canada's supply shortage. Furthermore, time for producing and transporting these isotopes was significant, especially given the short lifespan of these products. In short, Mr. Chair, it was not an option to meet Canada's demand from international suppliers, particularly since Chalk River produces more than half the world's supply.
Now that production and delivery has resumed, my officials are continuing our work with the expert advisory group to examine contingency plans in the event of any future supply disruption. This work includes assessing the possibility of alternative sources of medical isotopes, along with substitute diagnostic techniques that could be used if needed. In addition, this work is also looking at opportunities for enhancing international collaboration to coordinate supply. Our expert advisory group will be preparing its initial assessment in February. At that point, I intend to convene health care professionals, provincial and territorial representatives, and other experts to assess the lessons learned and discuss the work of the expert advisory group.
Of course, one very important issue to consider in all of this is timely information sharing. Going forward to ensure timely notification of issues that may affect supply, we have developed a notification protocol among AECL, Natural Resources Canada, and Health Canada. This protocol provides clarity about who needs to be contacted and when. As well, it states that information will be shared immediately when it concerns the operations of the Chalk River reactor and, as a result, the supply of medical isotopes.
Under the new protocol, once my department receives timely information about a potential supply impact, a process will be triggered to contact provinces, territories, and relevant experts to assess the potential impact and launch strategies to respond. We will also be more closely monitoring information from suppliers, along with clinical trial and import licence applications, all of which could be early warning signals of potential medical isotope supply issues.
Let me give you an example. Health Canada receives routine requests from companies, including medical isotope supply companies, seeking special importation permits to adjust to supply shortages. This request is not unusual, and in fact we received one on December 3 from a company that had made the same request twice before in the past year.
As I mentioned earlier, when we were faced with the situation of shortages in early December, we took responsible action. I want to thank members from all parties—the Liberals, the New Democrats, the Bloc along with my fellow Conservatives—in both the House of Commons and the Senate—for passing our legislation so quickly.
In closing, I want to reiterate my central point that we had to act. Repeated requests to the regulator to see about an expeditious hearing were not met. Consequently, with all-party support in Parliament, we passed the necessary legislation, and the CMA and the Canadian Society of Nuclear Medicine thanked us.
I will leave it at that and say that partisan considerations aside, we're all here to do the utmost for human health and well-being. It was in that spirit that I believe we acted with good sense.